Keymed Biosciences’ CM512 Receives Breakthrough Therapy Designation for CRSwNP by China NMPA 1
Keymed Biosciences Inc. – CM512 Receives Breakthrough Therap...
Sign in to continue:
Keymed Biosciences Inc. – CM512 Receives Breakthrough Therap...
KPa-BM Holdings Limited Annual Report 2026 – Investor Highli...
Ascletis Pharma Announces Preclinical Success of ASC36_35 FD...
CStone Pharmaceuticals: Directors & Management Share Purchas...
JX Energy Ltd. Issues Profit Warning: Significant Reduction ...
Sands China Ltd. Q2 2026 Financial Results: In-Depth Investo...
Minieye Technology Announces Placing of New H Shares to Acce...
Shanghai MicroPort MedBot Issues Positive Profit Alert: Firs...
Oshidori International Holdings Limited Issues Positive Prof...
ELL Environmental Holdings: Supplemental Announcement on Dis...